VEGFR-3, also known as fms related receptor tyrosine kinase 4 (FLT4), has been explored as a target for pancreatic cancer therapy [24,33] with significantly upregulated FLT4 expression documented in pancreatic cancer specimens [34,35]. This evidence concerns the gene FLT4 and pancreatic neoplasm.